The KOrean College of
Rheumatology BIOlogics and targeted
therapy (KOBIO)
registry is a nationwide observational cohort that captures detailed data on exposure of
patients to
biologic and targeted synthetic
disease-modifying
anti-rheumatic drugs (DMARDs). This
registry was launched in December 2012 with an aim to prospectively investigate clinical manifestations and outcomes of
patients with
rheumatoid arthritis (RA),
ankylosing spondylitis, and
psoriatic arthritis who initiated a
biologic or targeted synthetic
DMARD or switched to another.
Demographic data,
disease activity, current
treatment, adverse events, terms based on Medical
Dictionary for Regulatory Activities, and so on are registered for
patients who are then followed up annually in a web-based unified platform. The KOBIO
registry also recruits and collects data of
patients with RA on conventional DMARDs for comparison. As of today, more than 5,500
patients were enrolled from 47 academic and
community Rheumatology centers across
Korea. The KOBIO
registry has evolved to become a powerful database for clinical
research to improve clinical outcomes and quality of
treatment.